Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Drug Risk Versus Benefit

  |  Issue: April 2009  |  

Although Dr. Reyna lauded the current era of patients becoming active decision makers, she cautioned that physicians must not abrogate their responsibility in helping patients make informed choices. “Healthcare providers have to think very carefully about ‘the bottom line’ of the information they communicate to patients. They are in a very important role of conveying that information,” she concluded.

Gretchen Henkel covered the 2008 ACR/ARHP Annual Scientific Meeting for The Rheumatologist.

ADVERTISEMENT
SCROLL TO CONTINUE

Reference

  1. Reyna VF, Hamilton AJ. The importance of memory in informed consent for surgical risk. Med Decis Making. 2001;21:152-155.
  2. Lloyd A, Hayes P, Bell PRF, Naylor AR. The role of risk and benefit perception in informed consent for surgery. Med Decis Making. 2001;21:141-149.

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    FDA Provides 2020 Rheumatology Drug Update

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.